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82 Poster Session Ibetween the two groups with respect to age, gender, disease type, or
CMVstatus. Likewise, therewere no significant differences between
thePCTand control groupswith respect to donor source (related vs.
unrelated), progenitor cell source (BM vs. UCB) or HLA disparity.
In this cohort, PCT patients were more likely to have grade II-IV
aGVHD (86 vs. 35%, p 5 0.01) and grade III-IV aGVHD (35 vs.
15%, p 5 0.03). Similarly, PCT patients were more likely to have
cGVHD (36% vs. 13%, p 5 0.01). The cumulative incidence of
non-relapsemortality and overall survival at 5 yrs, however,was sim-
ilar in both groups (p5 0.29 and p5 0.12, respectively). In univar-
iate analysis, a significantly lower risk of relapse at 3 years was noted
in patients with PCT (0% vs. 30% [25–36%], p5 0.02). In Cox re-
gression, aGVHD (p5 0.05), cGVHD (p5 0.01) and development
of PCT (p\0.01) were associated with protection form relapse. Of
the 6 deaths in the PCT group, 5 patients had pulmonary complica-
tions at the time of death. Collectively these data suggest that pa-
tients with PCT are at high risk for cGVHD and pulmonary
associated toxicity, but lower risk of relapse.
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HYPERCALCEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR OSTEOPETROSIS
Martinez, C.1, Orchard, P.J.1, Wagner, J.E.1, Petryk, A.2, Tolar, J.1.
1University of Minnesota, Minneapolis, MN; 2University of Minnesota,
Minneapolis, MN.
Osteopetrosis (OP) is a clinical syndrome characterized by insuf-
ficient osteoclastic activity resulting in defective bone resorption
and marked increase in bone density. The recessive form of osteo-
petrosis (‘‘malignant osteopetrosis’’) has been successfully treated
with allogeneic hematopoietic cell transplantation (HCT), second-
ary to engraftment of donor-derived functioning osteoclasts result-
ing in bony remodeling and establishment of normal hematopoiesis.
While hypocalcemia is a common presenting feature of recessive os-
teopetrosis, hypercalcemia may be observed following HCT due to
rapid engraftment of osteoclasts differentiated from the hematopoi-
etic precursors. To investigate the incidence of hypercalcemia after
HCT, we have evaluated nine patients with osteopetrosis (a median
age of 2 years, range 0.5 – 28 yrs) treated at the University of Min-
nesota during a 7 year period (2000–2007). Eight patients were re-
ceiving their initial transplant, and one patient received a second
HCT, following graft failure. The conditioning regimen consisted
of busulfan, fludarabine, equine ATG and total lymphoid irradia-
tion. Donor grafts consisted of URD BM (2), URD UCB (3),
REL PBSC (2), and URD PBSC (2). All patients that received
a BM or PBSC graft engrafted with donor grafts, while recipients
of UCB had a transient partial engraftment followed by autologous
recovery. The median day of myeloid recovery (defined as an abso-
lute neutrophil count of 500 or above for 3 consecutive days) was
day 20 (range 14–42 days). Elevated calcium levels were found in
three of the nine patients. The elevation of calcium levels was ob-
served at a median day 12 (range 10–15) which correlated with ini-
tial count recovery. The median day of highest calcium levels in
these three patients was day 21 with a mean calcium level of 12.9
mg/dL (SD 1.18). Clinically, hypercalcemia was managed with in-
travenous fluids, furosemide diuresis and calcitonin. The median
age of the group of patients with hypercalcemia was 24 years. In
contrast the median age of the patients that didn’t experience hyper-
calcemia was 1 year of age. No correlation was found between hy-
percalcemia and type of donor graft, HLA match, or CD341 cell
dose. The implications of the current study are that hypercalcemia
occurs after HCT in approximately one third of theOP patients and
that it may be more common in older patients, perhaps due to age
dependent increase in bone mass.
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TOLERABILITY OF DAPSONE IN PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANT
O’Connor, M.R., Duncan, C., Myers, K., Lehmann, L. Dana-Farber
Cancer Institue, Boston, MA.
Dapsone is a commonly used drug for pneumocystis carinii pneu-
monia (PCP) prophylaxis in pediatric Hematopoietic Stem CellTransplant (HSCT) patients. However, its use is frequently limited
by toxicities such as hemolysis and methemoglobinemia. We per-
formed a retrospective medical record review of all pediatric
HSCT patients at our institution between January 1, 2001 and
June 8, 2007. We identified all patients that received dapsone as
PCP prophylaxis and documented course limiting adverse effects.
402 patients received 447 transplants during the study period. Dap-
sone was prescribed as PCP prophylaxis in 111 instances (24.8%). In
27.9% of these instances patients completed the recommended
course without incident. 72.1% of the time patients were changed
to an alternative prophylactic agent due to dapsone-associated ad-
verse events.Hemolysis was themost common reason for discontin-
uation of dapsone and it occurred in 41(36.9%) cases.
Methemoglobinemia was the second most common adverse effect
and it occurred in 27 (24.3%) instances. The mean methemoglobin
level for this group was 4.4% with a range of 2.2–16% (upper limit
of normal at our institution is 1.5%). Dapsone was discontinued in
the remaining patients because of rash (7), increased liver function
tests (1), and tachycardia and vertigo (1). Three patients were lost
to follow-up. In patients who received dapsone there were no docu-
mented cases of PCP.Dapsonewas an effective, yet poorly tolerated
agent in this group of pediatric stem cell transplant patients. Pro-
viders should maintain a high level of awareness for toxicities
when utilizing dapsone in pediatric stem cell transplant patients.221
PRELIMINARY RESULTS OF NON-ABLATIVE CONDITIONING (NAC)
WITH BUSULFAN (Bu), FLUDARABINE (Flu) AND ALEMTUZUMAB FOL-
LOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) TO
INDUCE MIXED DONOR CHIMERISM IN PATIENTS WITH SICKLE CELL
DISEASE (SCD)
Bhatia, M.1, Baldinger, L.1, Billote, G.1, Morris, E.1, Bradley, M.B.1,
George, D.1, Garvin, J.1, Satwani, P.1, Schwartz, J.1, Wolownik, K.1,
Foley, S.1, Hawks, R.1, Baxter-Lowe, L.A.2, Cairo, M.S.1. 1Columbia
University, New York, NY; 2UCSF, San Francisco, CA.
SCD is associated with a decrease in lifespan and quality of life in
children. The only known cure is AlloSCT from a matched family
donor with only 15% of patients having an unaffected, HLA-
matched identical sibling. Patients undergoing myeloablative Al-
loSCT are at risk for numerous complications post SCT including
death, graft versus host disease (GVHD), and infections. Full donor
chimerism is not necessary to correct the underlying genetic defect
and eliminate symptoms in patients with SCD. In this study, we re-
port the preliminary results of NAC and AlloSCT from related
matched family and unrelated umbilical cord blood (UCB) donors
in 7 patients (7M:0F) with high risk SCD (HbSS 5 4, HbSC 5 2,
HbSßThal 5 1). Conditioning was Bu (4 mg/kg  4 d # 4 yrs
and 12.8 mg/kg  4 d . 4 yrs), Flu (30 mg/m2  6 d), and Alemtu-
zumab (2 mg/m2 1 d, 6 mg/m2 2 d, and 25 mg/m2 2 d). UCB
recipients also received rabbit antithymocyte globulin (2 mg/kg 4
d). Mean age was 5.8 years 1/-4.03 (1.4–13.75 years). Donor sour-
ces were: 2 6/6 HLA-matched sibling bone marrow (BM), 2 6/6
HLA-matched UCB, and 3 4/6 unrelated UCB. Mean cell dose
was 12.021/-13.0  107 TNC/kg and 1.031/-1.66  106 CD34/
kg. Patients received tacrolimus and mycophenolate mofetil as
GVHD prophylaxis and phenytoin as seizure prophylaxis for 180
days post SCT. Of 5 patients evaluable for myeloid recovery (1
did not nadir, 1 too early), mean neutrophil and platelet recovery
was on day1306 7(n5 5) and day1606 18(n5 5), respectively.
One patient had primary graft failure at day 160 post SCT (Bu
steady state concentration (Css) 552 ng/ml). Busulfan pharmakoki-
netics were then changed to maintain Css between 600–900 ng/ml.
Mean whole blood donor chimerism on days 130, 160, and 1100
was 49%633(n5 6), 61%632(n5 5), and 82%613(n5 4), respec-
tively. More recently, erythroid engraftment (CD71) is being deter-
mined. Mean CD71 chimerism on days 130 and 160 was
55.3%641(n 5 3) and 61.1%617.5(n 5 3), respectively. Hb elec-
trophoresis was done on all patients with mean %HbS levels of
1.80 6 1.02(n 5 5) and 7.46 6 9.88(n 5 5) on days 130 and
1100, respectively. Grades II-IV acute GVHD was seen in 3/7 pa-
tients(42%). Chronic extensive GVHD was seen in 1/5(20%) pa-
tients. All patients are alive with the longest follow up being 1120
Poster Session I 83days post SCT. In summary, NAC and AlloSCT in patients with
SCD using both related and unrelated donors has been shown to
be well tolerated and effective in inducing a high degree of mixed
donor chimerism.222
DONOR CHIMERISM KINETICS IN PEDIATRIC PATIENTS UNDERGOING
REDUCED INTENSITY CONDITIONING (RIC) WITH ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Schneiderman, J.1, Rademaker, A.W.2, Chaudry, S.1, Tse, W.1,
Jacobsohn, D.A.1, Duerst, R.1, Kletzel, M.1. 1Children’s Memorial Hos-
pital, Northwestern University Fienberg School of Medicine, Chicago, IL;
2Northwestern University Feinberg School of Medicine, Chicago, IL.
From 9/03–9/07 fifty-three children with malignant (n5 31) and
non-malignant diseases (immune deficiencies, metabolic disorders,
severe aplastic anemia, n5 22) underwent RICHSCT; median age
at time ofHSCTwas 8 years (1 month - 17 years). RIC included flu-
darabine 30 mg/m2/d  5 d and targeted (AUC 4000 micorMol*-
min) single daily IV busulfanX2d (n 5 4), 1 ATG(n 5 34) or 2
weekly treatments of extracorporeal photopheresis (ECP, n 5 12).
Three received other fludarabine-based regimens. GVHD prophy-
laxis included CSA6MMF (n5 53),1 post-HSCT ECP (n5 12).
Neutrophil and platelet recovery were defined as 1st of three con-
secutive ANC . 500/ml and platelet count . 20,000/ml without
transfusion. Lineage specific chimerism assays of total white
cells(TW), T-cell (CD3), and myeloid cells (CD33) were moni-
tored serially post-HSCT by variable number tandem re-
peats(VNTR) assays. Full donor chimerism (FDC) was defined
as$95 1 5%, subsequent loss of full donor chimerism was defined
as a drop below 50%. Patients who did not reach 95% were termed
mixed chimerism. Neutrophil recovery occured in 94% at a median
of 18 days (4–39); one never fell below 500/ml. Platelet recovery was
evaluated in 52; 54% did not fall below 20,000/ l, 40% reached
20,000/ml (median 20 days, 9 – 158), and 38% reached 50,000/ml
(median 20.5 days, 11–142). Median cell doses per kilogram body
weight were as follows: CD34 6.77  106 (0.12 – 25.8), MNC
4.84 108 (0.27 – 8.85), and TNC8.15 108 (0.41 – 46.1). No cor-
relation between cell dose and neutrophil recovery was seen; signif-
icant correlation was seen between cell dose and platelet recovery
(CD34, p 5 0.009, MNC, p 5 0.05, TNC, p 5 0.02). Patients
who received RIC HSCT (Table 1) for malignant disorders when
compared with non-malignant disorders showed a significant differ-
ence in achieving FDC in TW (p 5 0.0002) and myeloid (p 5
0.0002) cell lines. Two lost TW chimerism (malignant n 5 1, day
46, non-malignant n 5 1, day 340). 17/53 achieved mixed chime-
rism (malignant n 5 4, non-malignant n 5 13); those with malig-
nant disease received second HSCT. Non-malignant patients
remain free of disease (2nd HSCT n 5 7). There is significant dif-
ference in achieving FDC in those pts with malignancies which may
be attributed to prior therapy. Stable partial chimerism may be suf-
ficient in pts with non-malignant diseases. Chimerism requires fre-
quent monitoring; interventions such as changing immune
suppression or donor lymphocyte infusions must be considered.Table 1.
Median MedianRIC With
Allo-HSCTFDC
TW (%)Median
Time to FDC
TW (days)FDC
T-cell (%)Time to
FDC T-cell
(days)FDC
Myeloid
Cell (%)Time to
FDC Myeloid
(days)All Patients
(n 5 53)68% 48 69% 99 75% 29Malignant
Diseases
(n 5 31)87% 33 82% 97 85% 26Non-Malignant
Diseases
(n 5 22)41% 383 52% 169 48% 167p 5 0.0002 p 5 0.1 p 5 0.0002223
ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKE-
MIA USING CAMPATH IN A MYELOABLATIVE CONDITIONING REGIMEN
Kennedy-Nasser, A.A., Myers, G.D., Leung, K.S., Gottschalk, S.,
Bollard, C.M., Heslop, H.E., Brenner,M.K., Krance, R.A. Baylor College
ofMedicine, Texas Children’s Hospital, TheMethodist Hospital, Houston,
TX.
Allogeneic transplantation from a matched sibling donor (MSD)
offers curative therapy for pediatric patients with acute lymphoblas-
tic leukemia (ALL); however, less than 30% of patients will have
a MSD. Alternative donor (AD) transplantation is a viable option
for these patients, but the risk for GVHD remains much higher.
From 2001 to present, we have used Campath in the conditioning
regimen for AD transplants to achieve in vivo T-cell depletion, in
an effort to reduce the risk of GVHD. Here we report the outcome
of pediatric ALL patients receiving AD transplants using Campath
as part of a myeloablative conditioning regimen. Risk assessment is
assigned prior to transplant – standard risk (SR) includes patients
with ALL in 1st or 2nd complete remission. Since 1997, 39 patients
with SRALLwere transplantedwithMSDgrafts, and since institut-
ing Campath in 2001, 39 patients have received AD grafts. AD pa-
tients received bone marrow or peripheral blood stem cell products
from up to 1 antigen mismatched related or unrelated donor. Mye-
loablative conditioning included cyclophosphamide, cytarabine
arabinoside and total body irradiation (1200 cGy for MSD and
1400 cGy for AD) in all patients with the addition of Campath in
the AD recipients. Additional GVHD prophylaxis consisted of
FK506 or cyclosporine with either methotrexate or prednisone.
All but one evaluable patient achieved neutrophil engraftment.
The 5-year disease-free survival for patients with MSD was 83%
compared to 60% for AD recipients. The 100-day mortality was
8% in the AD group and 3% in the MSD group. GVHD was low
in the AD cohort – 13% developed grade II-IV acute GVHD and
none developed extensive, chronic GVHD. Consistent with other
published reports using Campath, we did observe a high incidence
of viral infections – 28% developed adenovirus reactivation; 28%
developed CMV reactivation; and 3% developed EBV-LPD. We
conclude that Campath used with amyeloablative conditioning reg-
imen offers a curative option for pediatric patients with acute lym-
phoblastic leukemia requiring alternative donor transplantation
with a low incidence of GVHD.224
OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
Parikh, S.H.1, Mendizabal, A.2, Martin, P.L.1, Szabolcs, P.1,
Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1. 1Duke UniversityMedical
Center, Durham, NC; 2The EMMES Corporation, Rockville, MD.
Between 1995 and 2007, 24 pediatric patients were transplanted
with unrelated donor umbilical cord blood (UCB). M:F ratio was
1.4; the median age was 10.5 years (range 1.11–19.73). Median
time from diagnosis to transplant was 6.43 months (range 2.00–
61.37). Patients were followed for amedian time of 5.68 years (range
0.45–11.57). Eighty percent had primary disease. MDS stage was
RA/RC 12 pts, RAEB 8 pts and RAEB-T 4 pts. Monosomy-7 was
present in 18 (75%) patients. Patients with frank AML were ex-
cluded. Preparative regimen was TBI based in 19 (79%) patients
whileMelphalanwas used in 14 (58%) patients. GVHDprophylaxis
consisted of CSA/steroids (19 pts) and CSA/mycophenolate (5 pts).
Grafts were selected for matching at HLA Class I (A and B) at low
resolution and HLA Class II (DRB1) at the allelic level resulting in
17 (71%) 4/6 and 7 (29%) 5/6 matched transplants. The grafts con-
tained a median of 4.22  107 (range 1.68–12.58) total nucleated
cells (TNC)/kg pre-cryopreservation; 3.58  107 (range 1.01–
12.00) TNC/kg and 1.71 105/kg (range 0.17–28.46) CD341 cells
were infused. Cumulative incidence of neutrophil engraftment
(ANC . 500/mL) at Day 42 and Day 100 was 70.8% (95% CI
51.8%-89.8%) and 92.7% (95% CI 75.5%-100.0%), respectively,
and that of platelet engraftment (50K) at 180 days was 66.7%
(46.9%-86.5%). Three pts had graft failure while 4 pts (16%)
